Dr. Mudasir Rashid
APID: 2854
capPost Doctoral Researcher at HOWARD UNIVERSITY HOSPITAL Washington, DC
 

Expertise


Epi-genetic Techniques: Bisulfite conversion method, Methylated DNA Immunoprecipitation (MeDIP), HAT and HDAC assay. • Molecular Biology Techniques: Droplet Digital PCR (ddPCR), Real time-PCR. • Cell Culture and Cancer Biology Techniques: Handling mammalian cell cultures, Transfection, Luciferase assay, Proliferation assay (MTTs and Clonogenic assay), Migration/ Invasion assay (Wound healing, Boyden Chamber). • Analytical and Immunological Techniques: SDS-PAGE, AUT-PAGE, Western-blotting, Co-immunoprecipitation (Co-IP), Immunofluorescence (IF), Immunohistochemistry (IHC) and Micrococcal Nuclease assay (MNase), Comet assay. • Microbiology: Competent cell preparation, transformation, screening and plating, cloning (primer designing), site-directed mutagenesis (SDM), and Protein purification (using combination of ion exchange, size exclusion, and affinity chromatography techniques). Knock-in point-mutation using CRISPR-Cas9 HDR based methods. • RNA seq analysis: RNA isolation, cDNA synthesis, library preparation, adapter ligation, and data analysis.

Area of Interest


Epigenetics, Microbiome, Cancer biology-Colorectal cancer and saffron

Short Biography


I have extensive expertise in Cancer Biology, More Epigenetics, Biotechnology, Microbiome. I hold a Master of Science (MS) in Biotechnology from the University of Bangalore, India, and a Doctor of Philosophy (PhD) in life science with a focus on Cancer Biology, specifically Gastric Adenocarcinoma. Currently, I am working in Dr. Ashktorab’s laboratory as a Postdoctoral Researcher in Department of Medicine, Gastroenterology Division, Howard University Hospital Cancer Center, Washington DC, USA. During my doctoral studies, I focused on understanding the molecular profiles of histone H3 isoforms and variants in gastric adenocarcinoma and exploring novel pathways and potential therapeutic targets. At Howard University, I have conducted exome next-generation sequencing (NGS) on African American colorectal cancer (CRC) patients, leading to the identification of novel and deleterious MSH3 missense mutations, providing insights into their significance in AA-CRC pathogenesis.

Honors and Awards


User has not updated his/her Awards & Honors.

Career Timeline


User has not updated his/her Career Timeline.

Publications


User has not updated his/her Publications.

Projects


User has not updated his/her Projects.

Conference Details


User has not updated his/her Conferences.

Contributions


There are no views with that ID